Upcoming Earnings, Donations, FDA Approvals, Mortality Reduction Commitments, and New Monitoring Platform - Analyst Notes on Boston Scientific, ResMed, Edwards, Masimo and NuVasive

Editor Note: For more information about this release, please scroll to bottom

Jul 04, 2014, 06:40 ET from Analysts Review

NEW YORK, July 4, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Boston Scientific Corporation (NYSE: BSX), ResMed Inc. (NYSE: RMD), Edwards Lifesciences Corp. (NYSE: EW), Masimo Corporation (NASDAQ: MASI) and NuVasive, Inc. (NASDAQ: NUVA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4460-100free. -- Boston Scientific Corporation Analyst Notes On July 1, 2014, Boston Scientific Corporation (Boston Scientific) announced that it will hold a conference call to discuss its Q2 2014 financial results, as well as provide its financial outlook. The call, to be hosted by Mike Mahoney, President and CEO, and Dan Brennan, Executive Vice President and CFO, will be webcast on July 24, 2014 at 8:00 a.m. ET. The Company informed that a news release containing the results will be issued that same day prior to the call. A live webcast of the call will be made available at Boston Scientific's Investor Relations website, while its replay will remain on the site for around a year. The full analyst notes on Boston Scientific are available to download free of charge at: http://www.analystsreview.com/Jul-04-2014/BSX/report.pdf -- ResMed Inc. Analyst Notes On June 30, 2014, ResMed Inc. (ResMed) announced that it has donated more than 10,000 continuous positive airway pressure (CPAP) devices to the American Sleep Apnea Association (ASAA) CPAP assistance program (CAP). The Company informed that CAP is just one of the support programs offered to patients by the ASAA, and provides a package containing a CPAP device, tubing, filters and mask to patients who are financially unable to afford the obstructive sleep apnea (OSA) therapy equipments. ResMed CEO Mick Farrell said, "Making CPAP accessible to those who are in need helps us in our mission to improve the lives of those who are challenged by OSA and other sleep and respiratory conditions. We're grateful that the ASAA has a program that allows us to deliver donated devices to those who need them most." The full analyst notes on ResMed are available to download free of charge at: http://www.analystsreview.com/Jul-04-2014/RMD/report.pdf -- Edwards Lifesciences Corp. Analyst Notes On June 30, 2014, Edwards Lifesciences Corp. (Edwards) announced that it has received US Food and Drug Administration (FDA) clearance for its ClearSight system, a non-invasive monitor that provides clinicians access to blood volume and blood flow information for patients at moderate or high risk of post-surgical complications. Commenting on the clearance, Carlyn D. Solomon, Edwards' Corporate Vice President, Critical Care and Vascular, said, "The ClearSight system is the most advanced non-invasive monitor of its kind. This important development in the field of critical care medicine builds on Edwards' 40 years of experience in providing clinicians with tools to make more informed decisions that can advance patient care by helping to reduce complications, shorten hospital stays and lower associated costs." The full analyst notes on Edwards are available to download free of charge at: http://www.analystsreview.com/Jul-04-2014/EW/report.pdf -- Masimo Corporation Analyst Notes On June 27, 2014, Masimo Corporation (Masimo) announced its unconditional commitment to Every Newborn Action Plan (ENAP), to reduce global newborn mortality. Earlier in 2013, Masimo launched its first commercial, medical-grade Masimo SET Measure through Motion and Low Perfusion pulse oximeter technology iSpO2 Rx, in conjunction with the Newborn Foundation's BORN Project - Birth Oximetry Routine for Newborns. The Company informed that along with the Newborn Foundation, it has spent nearly two years working with public health officials, delivery hospitals, and clinicians to create the first viable, measure-through motion and low perfusion, mobile-enabled pulse oximetry technology that can be adopted as part of routine neonatal screening for hypoxemia. Annamarie Saarinen, co-founder and CEO of the Newborn Foundation, said, "We have found that this simple, non-invasive check of oxygen levels in newborns is among the most effective health measures that can be deployed to reduce newborn mortality." The full analyst notes on Masimo are available to download free of charge at: http://www.analystsreview.com/Jul-04-2014/MASI/report.pdf -- NuVasive, Inc. Analyst Notes On June 23, 2014, NuVasive, Inc. (NuVasive) announced the release of a next generation monitoring platform with computer-assisted surgery applications to enhance both speed and efficiency for spine surgery. The monitoring platform, called NVM5 V2.0, hosts a comprehensive set of intraoperative technologies specifically designed for spine surgery, which includes sensory monitoring modality (SSEP) for multimodality monitoring of the spinal cord and peripheral nerves, as well as refinements to the recently launched spinal rod-bending technology called Bendini. Some of the capabilities of the NVM5 platform include nerve avoidance during an XLIF procedure in order to navigate the psoas; nerve proximity information during pedicle cannulation and screw placement; computer-assisted, rod-bending technology; nerve root and spinal cord monitoring; and peripheral sensory nerve monitoring. Pat Miles, NuVasive President of Global Products and Services, said, "NVM5 Version 2.0 demonstrates our continued commitment to developing innovative, adjunctive technologies that assist in the safety and reproducibility of surgical outcomes for spine patients, while also improving operating room economics." The full analyst notes on NuVasive are available to download free of charge at: http://www.analystsreview.com/Jul-04-2014/NUVA/report.pdf -- About Analysts Review We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership. =============== EDITOR'S NOTES: =============== 1. This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com . 5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com . 6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review